Pharmaceutical compositions containing insulin
The invention provides a pharmaceutical composition for the oral administration of insulin comprising insulin, a bile acid or alkali metal salt thereof, the bile acid being selected from the group consisting of cholic acid, chenodeoxycholic acid, taurocholic acid, taurochenodeoxycholic acid, glycocholic acid, glycochenocholic acid, 3.beta.-hydroxy-12-ketocholic acid, 12.alpha.-3.beta.-dihydrocholic acid, and ursodesoxycholic acid, and a protease inhibitor, the composition being provided with an enterocoating to assure passage through the stomach and release in the intestine.
Latest Hadassah Medical Organization Patents:
- METALLO-DESFERRIOXAMINE COMPLEXES AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS
- Method for reversing age-related changes in heart muscle cells
- Heparanase derived from human Sk-Hep-1 cell line
- Method for the ablative reshaping of material surfaces
- Pharmaceutical composition for protecting the heart comprising a heterocyclic ethylenediamine derivative and methods for the use thereof
The present invention relates to a pharmaceutical composition containing insulin. More particularly, the present invention relates to a pharmaceutical composition for the oral administration of insulin.
Insulin is a medicament particularly useful as a hypoglycaemic agent being widely used by patients suffering from diabetes and is the only treatment for Juvenile diabetes mellitus.
In practice today insulin is administered only by injection. The everyday injection of insulin is very troublesome and causes considerable physical and even mental suffering for the patients. Several severe side effects such as lipodystrophy at the site of the injection, lipoatrophy, lipohypertrophy or occasional hypoglycemia have been noted and reported to occur.
To avoid the daily injection of the drug, the insulin pump has been developed in the last decade. This pump, however, also suffers from some of the disadvantages of the daily injection. Since insulin is normally secreted into the portal vein, normally the liver is exposed to a greater insulin concentration than peripheral tissues. Insulin administered via the peripheral venous system to insulin-deficient diabetic patients results in a concentration of insulin in the portal vein almost equal to that in the peripheral circulation. The net result is hypoinsulinemia in the portal vein and the liver and hyperinsulinemia in the peripheral venous system. This may lead to an abnormal pattern of glucose disposal.
In order to overcome the difficulties caused by injection of insulin, rectal administration of insulin has recently been proposed, studied and developed.
Shichiri et al. (J. Pharm. Pharmac. 30, 806-808, 1978), Bar-On et al. (Br. J. Pharmac. 73, 21-24, 1981), and others tested the hypoglyceaemic affect of insulin mixed with polyoxyethylen lauryl ether or polyoxtethylene-20-cetyl ether by administering through the rectum. Ziv et al (Life Sciences, 29, 803-809, 1981) tested the same effect with insulin mixed with bile salts. The insulin effected the blood glucose levels, by reduction of approximately 50%, with dose of 48 .mu./kg.
In a further article by Ziv, Kidron, Bar-On and Berry (Life Sciences, 31, pp. 2837-2841, 1982) insulin was used as a model for proteins in general to discover the theoretical question of protein absorption through the intestine and it was found that in the presence of the strong detergent effect of deoxycholic acid and soybean trypsin inhibitor, biologically active macromolecules such as insulin could be effectively absorbed from the intestine.
Similarly, in British Pat. No. 1,563,311 there is described and claimed a pharmaceutical composition for rectal administration which comprises insulin, a carrier suiting the composition for rectal administration, and an agent for increasing the rate of absorption of the insulin into the body on rectal administration of the composition, the agent comprising at least one material selected from (a) nonionic polyoxyethylene ether surface active agents having an HLB value of 6 to 19 and wherein the average number of polyoxyethylene units is 4 to 30, (b) anionic surface active agents, (c) cationic surface active agents, (d) ampholytic surface active agents, (e) bile acids and (f) alkali metal salts of bile acids and amounting to 0.001 to 0.5 times the weight of the carrier. In U.S. Pat. Nos. 4,434,159 and 4,164,573 there are described similar insulin containing pharmaceutical compositions for rectal administration.
Thus the administration of insulin through the portal system of the human rectum in suppository form or further along the intestinal tract, e.g., by enema-like introduction is suggested and taught by said articles and patent.
Nevertheless it has been found that only part of the insulin is absorbed through the portal system from the human rectum and rectal administration also represents a major inconvenience for the patient.
According to the present invention, there have now been developed pharmaceutical compositions for administering insulin which overcome all of the above-mentioned disadvantages of the prior art systems.
More specifically, there have now been discovered and provided according to the present invention pharmaceutical compositions for the oral administration of insulin comprising insulin, a bile acid or alkali metal salt thereof, said bile acid being selected from the group consisting of cholic acid, chenodeoxycholic acid, taurocholic acid, taurochenodeoxycholic acid, glycocholic acid, glycochenocholic acid, 3.beta.-monohydroxychloric acid, lithocholic acid, 3.alpha.-hydroxy-12-ketocholic acid, 3.beta.-hydroxy-12-ketocholic acid, 12.alpha.-3.beta.-dihydrocholic acid, and ursodesoxycholic acid, and a protease inhibitor, said composition being provided with an enterocoating to assure passage through the stomach and release in the intestine.
Thus there have now been discovered pharmaceutical compositions containing insulin which can be administered orally and which have the same effect as naturally secreted insulin on the blood glucose levels. The insulin administered according to the present invention reaches the intestine and is quickly absorbed in the body through the intestine and through the portal system to the liver. This absorption route is the most convenient way to administer the drug and it resembles the physiological secretion of insulin by the pancreas, thus enabling delicate control of the blood glucose level and the metabolic activities of the liver and the peripheral organs controlled by insulin.
Various attempts have been made in the past to administer insulin orally. In one study it was shown that administration of liposome-entrapped insulin caused a significant reduction of blood glucose levels in diabetic rats (Dapergolas, G. and Gregoriadis, Lancet ii, 824-827, 1976). Patel and Ryman (FEBS Letters, 62, 60-63, 1976) showed that insulin administered orally entrapped in liposomes is effective in diabetic rats. PapahadJopoulos and SJoka (U.S. Pat. No. 4,235,871) suggested to use liposomes to encapsulate insulin and Sears (U.S. Pat. No. 4,145,410) used synthetic phosphatidyl compounds to stabilize the liposomes against lipolysis.
Another approach for insulin enhanced activity is the addition of an adjuvant such as choline (which is not a bile salt) to the insulin injections (U.S. Pat. No. 2,563,070). This is totally different from oral administration with bile salts since the bile salts in an oral composition enhance the absorption of insulin from the intestinal luman to the blood circulation while with injectable solutions no such absorption takes place or is necessary and the function of chlorine which is different structurally and chemically from cholic acid is entirely different in said patent and is intended to delay the insulin absorption.
Thus it will be realized that none of the said publications teaches or suggests the novel pharmaceutical composition of the present invention which includes the use of bile salts to promote the absorption of insulin, the use of protease inhibitors to protect insulin against proteolysis and the use of enterocoating of the active mixture.
Human insulin including human insulin genetically reproduced or any insulin such as, for example, the insulin obtained from cows (bovine), pigs or whales can be used as the insulin for compositions of this invention. Furthermore, metal complexes of insulin such as the zinc complex of insulin as well as protamine zinc insulin and globin zinc insulin may be also used as the insulin in compositions of this invention.
The protease inhibitor used in the compositions of the present invention can be any material which has the ability to inhibit any proteolytic activity.
Practical examples of such protease inhibitors include aprotinin (Trasilol.RTM. of Bayer), Pentamidine isethionate, antipain, tosylamide-phenylethyl-chloromethyl ketone (TPCK), phenylmethyl sulfonyfluoride (PMSF), pepstatin, trypsin inhibitor, Acetone, Alcohols, guanidium, a.sub.2 -macroglubulin, TLCK, Chelating agents of Zn, Iodoacetate, a.sub.1 -antitrypsin, EDTA, Zn, Antithrombin III, leupeptin, Trypsin inhibitor from soy bean, trypsin inhibitor from hen egg white, trypsin inhibitor from chicken egg white, etc.
Some of the above protease inhibitors might be toxic in large doses and therefore, if chosen the use and dosage thereof must be carefully screened and tested.
In expecially preferred embodiments of the present invention said protease inhibitor is selected from the group consisting of aprotinin, A.sub.2 -macroglobulin, antithrombin III and trypsin inhibitor from soy bean or chicken egg white.
The most preferred protease inhibitor agents used in this invention are preferably Trasylol.RTM. in the amount of 1000 k.i.u./100 mg pill, or 3 mg soybean trypsin inhibitor or 10 mg soybean flour.
The above-mentioned bile acids and alkali metal salts thereof used in the oral compositions of the present invention promote the absorption of the insulin from the intestinal tract and act as carriers therefor, however, it was interesting and surprising to note that deoxycholic acid, which was the acid of choice in the article in Life Sciences, Vol. 31, pp. 2837-2441 (1982) is unsuitable for use in the oral compositions of the present invention because of the damage which it causes to the cells of the intestinal wall.
The active concentration of bile acid or salt thereof is about 1-20 mg/ml and preferably about 5-15 mg/pill/one treatment.
It has also been surprisingly found that sodium cholate can simultaneously function both as the bile acid carrier of the insulin and the protease inhibitor agent and thus a composition comprising insulin and sodium cholate in an enteric coating is especially preferred.
The amount of insulin in a composition is 20-50 u/kg in rats and expected to be about 0.5-3 u/kg in humans. Preferred dosages for humans are about 1-2 u/kg/treatment with three treatments a day, however sustained release microencapsulation could allow treatment to be reduced to once or twice a day.
The enterocoating and possible microencapsulation of the mixture provides protection for the insulin against decomposition in the stomach and for the slow release of the mixture constituents in the intestinal tract.
The enterocoating is carried out by methods known per se in the art, e.g., according to Remington Pharmaceutical Sciences, p. 1614-1615 (1975, 15th Ed. Mack Pub. Co.) and Theory and Practice of Industrial Pharmacy, Lackman, Liberman & Canig, p. 116-117, 371-374 (1976, 2nd Ed.) as is the enteric microencapsulation (Theory and Practice of Industrial Pharmacy ibid, pp. 420-438).
One of the findings of the present invention is that there is different rate of absorption of the different constituents of the present composition from the intestinal lumen into the blood stream. The absorption of the bile acid is very fast, e.g., more than 50% of cholic acid is absorbed during 30 minutes while only 5-10% of the insulin is absorbed during 60 minutes.
For this reason a drug regimen involving ingestion of a pair of pills at spaced intervals, e.g., a second pill containing a higher concentration of bile acid to be taken half an hour after the first pill is contemplated as is microencapsulation of different constituents with spaced time release coatings to enhance the absorption of the insulin into the system.
While the invention will now be described in connection with certain preferred embodiments in the following examples it will be understood that it is not intended to limit the invention to these particular embodiments. On the contrary it is intended to cover all alternatives, modifications and equivalents as may be included within the scope of the invention as defined by the appended claims. Thus, the following examples which include preferred embodiments will serve to illustrate the practice of this invention, it being understood that the particulars shown are by way of example and for purposes of illustrative discussion of preferred embodiments of the present invention only and are presented in the cause of providing what is believed to be the most useful and readily understood description of formulation procedures as well as of the principles and conceptual aspects of the invention.EXAMPLE 1
An enterocoated capsule was prepared for oral administration of insulin to a diabetic dog. Table 1 shows Plasma 1R1 levels and glucose levels with administration.
TABLE I ______________________________________ Composition of this invention Test Time Glucose Insulin No. Formulation (Min) mm .mu.m/ml ______________________________________ Oral administration 1. insulin 7.3 u/kg 0 36.7 15 cholate 30 mg 15 33.9 0 soybean- 30 34.4 6 trpsin inhibitor 45 34.6 6 20 mg 60 33.8 12 in two capsules 75 29.1 23 (enterocoated) 105 23.7 36 135 21.8 22 65 16.1 3 210 15.8 0 240 11.5 0 270 12.1 0 300 10.2 0 330 7.5 0 360 9.3 0 ______________________________________
TABLE II ______________________________________ COMPARISON Test Time Glucose Insulin No. Formulation (Min.) mm .mu.m/ml ______________________________________ Insulin 0.5 u/kg 0 28.7 0 intramuscular 10' 23.3 73 injection 20' 21.5 76 30' 19.9 213 45' 15.6 220 60' 12.9 81 75' 10.9 120 90' 8.5 61 120' 6.5 50 150' 6.4 18 180' 6.5 25 ______________________________________COMPARISON EXAMPLE A
A solution was prepared for direct intestinal administration of 0.5 ml in final volume. In the rat.
TABLE III ______________________________________ Compositions of this invention Percent decrease in blood glucose No. of Test 60 120 240 Animals No. Formulation min min min tested ______________________________________ Injection of 0.5 ml into the ileum 1. Insulin 24 u/kg -33 -11 +11 5 sodium cholate 1% Trasylol 3000 K.I.U. in saline 2. Insulin 24 u/kg -23 -19 +10 4 sodium cholate 1% - in saline 3. Insulin 24 u/kg -18 -24 -2 6 sodium cholate 0.5% Trasylol 3000 K.I.U. in saline 4. Insulin 48 u/kg -34 -20 +10 10 sodium cholate 1% in saline 5. Insulin 48 u/kg -55 -50 +3 6 sodium cholate 1% Trasylol 1000 u in salin 6. Insulin 48 u/kg -61 -66 -25 6 sodium cholate 1% Trasylol 3000 u in saline 7. Insulin 48 u/kg -35 -28 +14 6 sodium cholate 1% Soybean trypsin- inhibitor 3 mg in saline 8. Insulin 48 u/kg -7 -2 +27 8 sodium taurocholate 1% in saline 9. Insulin 48 u/kg -28 -20 +21 6 sodium taurocholate 1% Trasylol 1000 K.I.U. in saline 10. Insulin 48 u/kg -39 -36 +3 7 sodium taurocholate 1% Trasylol 3000 K.I.U. in saline 11. Insulin 48 u/kg -15 -12 +21 6 Sodium taurocholate 1% Soybean trypsin- inhibitor 3 mg in saline 12. Insulin 48 u/kg -33 -30 +4 6 Trasylol 3000 K.I.U. in saline Control-intestinal administration 13. Insulin 48 u/kg -5 -6 +25 6 in saline ______________________________________
As is clear from the tables the effect of intestinal administration of insulin on blood glucose levels is similar to the effect of insulin injected to the animals. The effect is similar when insulin is given orally to the dog or directly into the intestine of the rat.
Enterocoating provides the sufficient shelter against the destruction of the insulin in the stomach and delays its effect for one hour in the dog.
Now the following examples illustrate practically the pharmaceutical compositions of insulin for oral use embodying this invention, wherein the dosage of insulin employed are for the human bodies.
All examples are for one pill or one capsule containing total weight of 100 mg. The active compounds will be given in detail. The complimentary weight is of inert compounds like manitol or avicel 101.
Thus the active ingredients and the vehicle for oral administration of compositions according to the present invention are hereinafter set forth in tabular form:
__________________________________________________________________________ Amount Bile Protease Example Insulin Acid/Salt Inhibitor Vehicle __________________________________________________________________________ 2. 100 I.U. 15 mg. sodium cholate -- enterocoated capsule 3. 100 I.U. 15 mg. sodium cholate aprotinin enterocoated 1000 K.I.U. capsule 4. 100 I.U. 15 mg. sodium cholate aprotinin enterocoated 3000 K.I.U. capsule 5. 100 I.U. 15 mg. sodium cholate 5 mg. soybean enterocoated trypsin inhibitor capsule 6. 100 I.U. 15 mg. sodium cholate -- enterocoated pills 7. 100 I.U. 15 mg. sodium cholate aprotinin enterocoated 1000 K.I.U. pills 8. 100 I.U. 15 mg. sodium cholate aprotinin enterocoated 3000 K.I.U. pills 9. 100 I.U. 15 mg. sodium cholate 5 mg. chicken egg enterocoated white pills trypsin inhibitor 10. 100 I.U. 15 mg. sodium tauro- aprotin enterocoated cholate 1000 K.I.U. capsule 11. 100 I.U. 15 mg. sodium tauro- aprotinin enterocoated cholate 3000 K.I.U. capsule 12. 100 I.U. 15 mg. sodium tauro- 5 mg. soybean enterocoated cholate trypsin inhibitor capsule 13. 100 I.U. 15 mg. sodium tauro- aprotinin enterocoated cholate 1000 K.I.U. pills 14. 100 I.U. 15 mg. sodium cheno- aprotinin enterocoated deoxycholate 1000 K.I.U. capsule 15. 100 I.U. 15 mg. sodium cheno- aprotinin enterocoated deoxycholate 3000 K.I.U. capsule 16. 100 I.U. 15 mg. sodium cheno- 5 mg. soybean enterocoated deoxycholate trypsin inhibitor capsule 17. 100 I.U. 15 mg. sodium cheno- aprotinin enterocoated deoxycholate 1000 K.I.U. pills 18. 100 I.U. 15 mg. sodium cheno- aprotinin enterocoated deoxycholate 3000 K.I.U. pills 19. 100 I.U. 15 mg. sodium cheno- 5 mg. soybean enterocoated deoxycholate trypsin inhibitor pills __________________________________________________________________________EXAMPLES 20 and 21
The following intercoated tablets were prepared in the following manner:
______________________________________ Component Example 20 Example 21 ______________________________________ Insulin 2 mg 2 mg Sod. Cholate 15 mg 15 mg Trasilol -- 1000 U Lactose Hydrous USP 144 mg 150 mg Starch NF 36 mg 30 mg Magnesium Stearate NF 3 mg 3 mg Eudragit L-100 4 mg 4 mg (Polymer of Acrylic and Methacrylic Acid Esters) Talc NF 4 mg 4 mg Polyethylene Glycol 6000 NF 0.4 mg 0.4 mg Total 208.4 mg 208.4 mg ______________________________________
Method of Preparation:
(a) In order to homogeneously disperse the active components triturations with lactose for each component were individually prepared. Gradual dry mixing of all the components was then performed. The components are then mechanically pressed to form tablets of 9 mm diameter;
(b) A solution of the enterocoating polymer is then prepared by solving the polymer in a methylene chloride + isopropyl alcohol mixture. The tablets are coated by spraying the solution within a mildly warmed jar while the tablets roll. The solvent vapors are continuously aspirated.Testing the Tablets
The dissolution of the tablets was then tested according to USP XX. The tablets were found to be stable for two hours in gastric juices. When they are then transferred to intestinal juices, they dissolve there in less than 1/2 an hour.
It will be evident to those skilled in the art that the invention is not limited to the details of the foregoing illustrative embodiments and examples and that the present invention may be embodied in other specific forms without departing from the essential attributes thereof, and it is, therefore, desired that the present embodiments and examples be considered in all respects as illustrative and not restrictive, reference being made to the appended claims, rather than to the foregoing description, and all changes which come with the meaning and range of equivalency of the claims are, therefore, intended to be embraced therein.
1. A pharmaceutical composition for the oral administration of insulin comprising insulin, a bile acid or alkali metal salt thereof which does not cause the damage to the cells of the intestinal wall caused by deoxycholic acid, said bile acid being selected fom the group consisting of sodium cholate cholic acid, chenodeoxycholic acid, taurocholic acid, taurochenodeoxycholic acid, glycocholic acid, glycochenocholic acid, 3.beta.-monohydroxychloric acid, lithocholic acid, 3.alpha.-hydroxy-12-ketocholic acid, 3.beta.-hydroxy-12-ketocholic acid, 12.alpha.-3.beta.-dihydrocholic acid, and ursodesqxycholic acid, and a carefully screened and tested dosage amount of protease inhibitor, said composition being provided with an enterocoating to assure passage through the stomach and release of insulin in the intestine.
2. A pharmaceutial composition for the oral administration of insulin according to claim 1 wherein said protease inhibitor is selected from the group consisting of sodium cholate aprotinin, A.sub.2 -macroglobulin, antithrombin III and trypsin inhibitor from soy bean or chicken egg white.
3. A pharmaceutical composition for the oral administration of insulin according to claim 1 comprising sodium cholate as both the bile acid and the protease inhibitor.
4. A pharmaceutical composition for the oral administration of insulin according to claim 1 wherein the components of said composition are microencapsulated and enterocoated to provide for timed release of ingredients in the intestine.
- Sarrach Stud. Biophys 100(2):95-102 (1984). Leung et al., Artif. Organs 7(2): 208-212 (1983). Chang, J. Bioeng. 1(1):25-32 (1976). Ziv et al., Life Sci. 29(8):803-809 (1981).
Filed: May 9, 1984
Date of Patent: Apr 1, 1986
Assignee: Hadassah Medical Organization
Inventors: Miriam Kidron (Jerusalem), Ehud Ziv (Motza Ilit), Hanoch Bar-On (Jerusalem), Amiram Eldor (Jerusalem)
Primary Examiner: Shep K. Rose
Law Firm: Darby & Darby
Application Number: 6/608,462
International Classification: A61K 950; A61K 928; A61K 3726;